ABBOTT PARK, Ill., Aug. 10, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure). Over time, narrowed kidney ...

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

Abbott today announced it has received U.S. Food and Drug Administration approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis in patients with uncontrolled hypertension .

Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company's U.S. clinical trial of renal denervation with the Symplicity® Catheter SystemT for the treatment of resistant hypertension (high blood pressure in the presence of three or more medications), an especially dangerous disease ...

Drug-maker Lupin Ltd said on Wednesday that it has got an approval from the regulator United States Food and Drugs Administration (USFDA) to manufacture and sell its generic version of hypertension drug Amlodipine/Benazepril.